Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction

Ravikumar Muthuswamy¹, Liwen Wang¹, Jamie Pitteroff¹, Jeffrey R Gingrich² and Pawel Kalinski¹,3,4,5,6*

Abstract

Background: BCG is a prototypal cancer immunotherapeutic factor currently approved of bladder cancer. In attempt to further enhance the effectiveness of immunotherapy of bladder cancer and, potentially, other malignancies, we evaluated the impact of BCG on local production of chemokines attracting the desirable effector CD8⁺ T cells (CTLs) and undesirable myeloid-derived suppressor cell (MDSCs) and regulatory T(reg) cells, and the ability of bladder cancer tissues to attract CTLs.

Methods: Freshly resected bladder cancer tissues were either analyzed immediately or cultured ex vivo in the absence or presence of the tested factors. The expression of chemokine genes, secretion of chemokines and their local sources in freshly harvested and ex vivo-treated tumor explants were analyzed by quantitative PCR (Taqman), ELISAs and immunofluorescence/confocal microscopy. Migration of CTLs was evaluated ex vivo, using 24-transwell plates. Spearman correlation was used for correlative analysis, while paired Students T test or Wilcoxon was used for statistical analysis of the data.

Results: Bladder cancer tissues spontaneously expressed high levels of the granulocyte/MDSC-attractant CXCL8 and T(reg)-attractant CCL22, but only marginal levels of the CTL-attracting chemokines: CCL5, CXCL9 and CXCL10. Baseline CXCL10 showed strong correlation with local expression of CTL markers. Unexpectedly, BCG selectively induced only the undesirable chemokines, CCL22 and CXCL8, but had only marginal impact on CXCL10 production. In sharp contrast, the combination of IFNα and a TLR3 ligand, poly-I:C (but not the combinations of BCG with IFNα or BCG with poly-I:C), induced high levels of intra-tumoral production of CXCL10 and promoted CTL attraction. The combination of BCG with IFNα + poly-I:C regimen did not show additional advantage.

Conclusions: The current data indicate that suboptimal ability of BCG to reprogram cancer-associated chemokine environment may be a factor limiting its therapeutic activity. Our observations that the combination of BCG with (or replacement by) IFNα and poly-I:C allows to reprogram bladder cancer tissues for enhanced CTL entry may provide for new methods of improving the effectiveness of immunotherapy of bladder cancer, helping to extend BCG applications to its more advanced forms, and, potentially, other diseases.

Keywords: Tumor microenvironment, Immunomodulation, Chemokines, BCG, TLR3, Poly-I:C, IFNα, Bladder cancer, Effector T cells, Regulatory T cells

* Correspondence: kalinski@upmc.edu
¹Departments of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
²Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA 15213, USA
Full list of author information is available at the end of the article

© 2015 Muthuswamy et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Bladder cancer, originating from the transitional cells of the bladder urothelium, accounts for an estimated 72,570 new cases and 15,210 deaths in the US. Though bladder cancer is highly treatable if found early, it becomes increasingly difficult to treat at later stages. Intravesicular BCG administration has been the standard therapy for treatment of bladder cancer, but its effectiveness is limited only to superficial bladder cancers [1-4].

Tumor infiltration with effector CD8+ T cells (CTL) has been associated with good prognosis in various cancers [5-18], therefore immunotherapies able of enhancing intra-tumoral CTL levels may also be effective for invasive bladder cancers. Previous studies by us [19] and others [10,20-25] have shown that intra-tumoral expression of chemokines regulate local levels of CTL infiltration, suggesting that T cell-targeting immunotherapies can benefit from modulating tumor-associated chemokine microenvironments in order to enhance local CTL infiltration.

Since myeloid-derived suppressor cell (MDSCs) and regulatory Treg cells are both known to protect tumors from CTL-mediated elimination and to promote tumor growth, ideal immunotherapies should be able to selectively enhance tumor production of CTL-attracting chemokines, without enhancing local levels of CXCL8, CXCL12 and CCL22, the chemokines mediating local attraction of MDSC and Treg to tumors [26-30]. Prompted by the above considerations, we evaluated the ability of BCG and alternative adjuvants to reprogram local chemokine milieu in bladder cancer to enhance the overall magnitude of local production of CTL-attracting chemokines in relation to MDSC/Treg-attractants. Unexpectedly, we observed that BCG, used alone, not only failed to enhance local expression of CTL-attracting chemokines, CCL5 and CXCL10, but selectively enhanced MDSC- and Treg-attracting chemokines, CCL22 and CXCL8. These undesirable side-effects could be reversed by the combination of IFNα and poly-I:C (TLR3 ligand), raising the possibility of enhancing the effectiveness of the BCG-based and other forms of immunotherapy of bladder cancer and potentially other malignancies.

Results

Bladder cancer tissues spontaneously produce MDSC- and Treg-attracting CXCL8 and CCL22, but not effector T cell-attracting chemokines

In order to evaluate the spontaneous chemokine expression and determine the baseline chemokine production pattern in bladder tumors, we isolated RNA from resected tumors of bladder cancer patients (N = 20) and performed real-time PCR (Taqman) analysis for the chemokines previously implicated in CTL or MDSC/Treg attraction to tumor lesions [26-30]. We observed that bladder tumors uniformly expressed only low levels of CTL attracting chemokines: CCL5, CXCL9, and CXCL10 (respective ligands for CXCR3 and CCR5 and CXCR3 [19]). In a striking contrast to the above CTL-attractants, the chemokines implicated in attracting MDSCs and Treg, CCL2 (MCP-1), CCL22 (MDC) and CXCL8 (IL-8) were highly expressed chemokines (Figure 1A), with CXCL8 uniformly expressed at the highest levels. The prevalence of high CCL22 and CXCL8 in bladder tumors at baseline is consistent with previous studies [31-33] which showed the abundance of these undesirable chemokines, particularly in patients with poor prognosis. High intra-tumoral expression of CXCL8 was confirmed by confocal analysis of tumor samples (Figure 1C). Taqman analysis for different markers of immune infiltrate (Figure 1B), using primers for CD4, CD8, GZMB and T-bet (effector cell markers), CD33 (myeloid marker), GITR (Treg marker) and NCF2 (myeloid or neutrophil marker) revealed that NCF2 expression was dominant, corresponding to the high IL-8 levels (see below).

Intra-tumoral expression of CCL5, CXCL9, and CXCL10 shows a strong correlation with CTL markers CD8 and Granzyme B

In order to test if the spontaneous expressed nominal CTL-attracting chemokines indeed predict local CTL infiltration in bladder cancer tissues, we attempted to correlate intra-tumoral mRNA expression of CCR5 ligands and CXCR3 ligand (CCL5, CXCL9 and CXCL10) with Intra-tumoral mRNA expression of CTL markers. As shown in Figure 2, Spearman correlative analysis of the chemokines and CTL markers revealed strong correlation between CD8 and Granzyme B with CCL5, CXCL9 and CXCL10. As expected, neither of these markers was correlated with the local expression of a Treg-attractant, CCL22 (data not shown). The levels of IL-8 expression were strongly correlated with NCF2 expression (neutrophil marker; Additional file 1: Figure S1).

BCG treatment of bladder tumors up regulates CXCL8, CCL22 expression, but not CXCL10

Using CXCL10 as a representative of CTL-attracting chemokines, involved in attraction of CXCR3+ CTL implicated with good prognosis for cancer patients [7,11,12,15], we tested whether BCG treatment can enhance intra-tumoral production CXCL10. Unexpectedly, we observed that, while BCG strongly up regulated the secretion of CXCL8 (P < 0.05) and CCL22 (P < 0.05) by ex vivo-treated bladder cancer explants (n = 11 patients), it did not enhance CXCL10 secretion (Figure 3).
Combination of IFNα + poly-I:C reverses the BCG-driven enhancement of undesirable chemokines

Since we have previously demonstrated that the combination of IFNα with poly-I:C effectively upregulated CTL chemokines in colorectal cancer tissues [19], we tested whether their addition to BCG can enhance its effectiveness. In a preliminary set of experiments we used an in vitro model system involving TS4 bladder...
cancer cells, blood isolated monocytes and fibroblasts (Additional file 1: Figure S3) to directly compare multiple combinatorial adjuvants in a single experiment, without the limitation imposed by the amount of bladder cancer tissues available from resections and their variability between different patients. In accordance with the data from our bladder cancer explant cultures, BCG alone was completely ineffective in promoting CXCL10 secretion in such cell cultures. In contrast, we observed strong synergy between IFN$\alpha$ and poly-I:C in promoting CXCL10 secretion, both in the absence and in the presence of BCG (Additional file 1: Figure S3). Importantly, neither the combination of BCG with poly-I:C nor the combination of BCG with IFN$\alpha$ was effective, which may explain the limited effectiveness of that later combination in the recently-completed clinical trial [4,34,35].

In accordance with these observations, our experiments performed in the tumor tissue explant model (n = 6 patients), demonstrated that in contrast to BCG, the combination of IFN$\alpha$ and poly-I:C strongly elevated tumor secretion of CXCL10. The combination of BCG with IFN$\alpha$ + poly-I:C resulted in only marginal or no further enhancement of CXCL10 secretion, but was associated with the undesirable elevation of CCL22 (Figure 4).

IFN$\alpha$ + poly-I:C-treated tumors show enhanced attraction of effector CD8$^+$ cells

To test whether the modified chemokine production patterns in BCG- and IFN$\alpha$ + poly-I:C-treated bladder cancer tissues result in their differential ability to attract CTLs, supernatants of the differentially-treated bladder cancer tissues were tested for their ability to attract
**Figure 3** BCG exposure of bladder tissues does not induce CXCL10, but further enhances tumor production of MDSC/Treg-attracting CCL22 and CXCL8. Bladder tumor biopsies were cultured in the absence or presence of BCG (2 × 10⁶ CFU) for 24 hours. CXCL10, CCL22 and CXCL8 proteins in tumor supernatants were measured by ELISA and expressed as ng/ml. The results were evaluated using two-tailed, paired Student’s t test. Statistically significant differences between groups are highlighted by * (P < 0.05). NS-Not significant.

**Figure 4** Combination of IFNα with poly-I:C is a powerful inducer of CXCL10 in bladder cancer lesions in the absence or presence of BCG. Bladder tumors biopsies were cultured for 24 hours in the absence or presence of 10,000 units IFNα + 20 μg/ml specific poly-I:C, with or without BCG (2 × 10⁶ CFU). The levels of CXCL10 and CCL22 in tumor supernatants were measured by specific ELISAs. The results were evaluated using two-tailed, paired Wilcoxon Test. Statistically significant differences between groups are highlighted by * (P < 0.05).
ex vivo-induced effector CD8\(^+\) T cells (pre-activated by SEB-loaded LPS + IFN\(\gamma\) matured DCs, capable of high IL-12 production [36,37]). As expected, bladder cancer tissues (n = 3 patients) treated with IFN\(\alpha\) + poly-I:C significantly attracted more of the effector CD8\(^+\) T cells than untreated or BCG alone treated tumors (Figure 5). The combination of BCG with IFN\(\alpha\) + poly-I:C didn’t further increase the CTL attraction. These data indicate that BCG by itself is insufficient to reprogram the bladder cancer-associated chemokine environment for enhanced CTL attraction, but that such goal can be achieved by the combination of BCG with (or its replacement by) IFN\(\alpha\) plus poly-I:C.

**Discussion**

BCG is a prototypal cancer immunotherapeutic factor which has been widely demonstrated to be effective in the treatment of superficial bladder cancer [1-4]. In attempt to further enhance the effectiveness of the immunotherapy of bladder cancer, including its more advanced stages, and potentially other malignancies, we evaluated the impact of BCG on local production of the chemokines attracting the desirable effector CD8\(^+\) T cells and undesirable MDSCs and T\(_{\text{reg}}\) cells.

We observed that bladder cancer tissues spontaneously expressed high levels of T\(_{\text{reg}}\)- and MDSC-attracting chemokines (CCL2, CCL22 and CXCL8, respective ligands for CCR2, CCR4 and CXCR1/2), but only low levels of CTL- attracting chemokines (CCL5, CXCL9-10; respective ligands for CCR5 and CXCR3), suggesting that the chemokine imbalance can contribute to the pathogenesis of bladder cancer and may limit the effectiveness of its immunotherapies. Unexpectedly, despite the documented beneficial role of BCG in bladder cancer, our data indicate that its ability to modify the microenvironment of bladder cancer ex vivo is largely limited to the enhancement of local production of T\(_{\text{reg}}\)- and MDSC-attracting chemokines, CCL22 and CXCL8, without inducing CXCL10 or facilitating CTL attraction. Our current data is consistent with the previous observations that bladder cancer tissues do not produce the desirable chemokine CXCL10 within the first week of BCG treatment, although can produce this factor after 3 weekly doses of BCG [38]. They are also consistent with the previous observations that bladder cancer lesions typically produce high levels of CCL22 and CXCL8 at baseline [31-33,39,40], which may be further amplified by treatment of patients with BCG and particularly by treatment with BCG combined with chemotherapy [32], constituting the undesirable side-effect of treatment [33]. Since intratumoral expression of CXCL8 has been shown to be a negative prognostic marker [31], these observations highlight a potential for...
targeting the bladder cancer-associated chemokine micro-environments to improve the outcomes of BCG-treatment and chemotherapy of this cancer type.

This selective activity of BCG may result from its dominant pattern of TLR2-mediated signaling [41], which has been shown to induce significantly less type-1 interferons compared to other TLR ligands [42,43]. In accordance with this possibility, our observations suggest that the combination of IFNα with poly-I:C (a TLR3 ligand) or BCG + IFNα + poly-I:C (although neither BCG + IFNα nor BCG + poly-I:C) are highly effective in enhancing intra-tumoral production of CXCL10 in bladder cancer tissues and promoting CTL infiltration. Interestingly, both these effective combinations showed at least partial selectivity in inducing CXCL10 (rather than CCL22) in cancer tissues. Our current experiments aim to determine if the additional inclusion of COX inhibitors (which proved to be effective in suppressing local production of CCL22 in metastatic colon cancer lesions [19]) with the currently-evaluated BCG + IFNα + poly-I:C combination will further potentiate its effectiveness by suppressing COX-2 dependent production of CCL22, CXCL8 and boosting induction of CXCL10 and other CTL-attracting factors.

Conclusion
Our current data suggest that the suboptimal ability of BCG to reprogram cancer-associated chemokine environments may represent a factor limiting its clinical activity, especially in more advanced stages of bladder cancer, and may represent an area of additional therapeutic intervention. Our identification of the combination of IFNα and poly-I:C, as factors which may supplement (or replace) BCG in effective reprogramming of cancer tissues for enhanced CTL entry, may help to improve the effectiveness of immunotherapy of bladder cancer and enhance the applications of BCG to its more advanced forms, as well as other malignancies or other disease states (such as mycobacterial infections), where the current BCG-based therapeutic regimens are not effective.

Methods

Ex vivo culture of bladder tumor explant tissues
Tumor from patients was obtained by informed consent under the IRB approved protocol UPCI 86–022. Patient clinical characteristics and sets of patients used for specific types of experiments are given in Table 1 below.

Using a 2 mm biopsy punch knife, uniform 2 mm cubes of resected tumor tissue were made. Tumor explants were assorted as 3 × two mm cubes/wells in 48 well plate respectively and cultured in IMDM plus 10% FBS, either untreated or treated with 2 × 10^6 CFU of BCG (TICE® BCG, Schering Plough, NJ) and/or 10,000 units of IFNα (Merck, NJ), 20 μg/ml of poly-I:C (Sigma Aldrich, St. Louis, MO). Tumor tissue biopsies were harvested at 0 and 24 hours for mRNA and confocal microscopy analysis and culture supernatants were harvested at 24 hours for ELISA.

Bladder cancer cell line-macrophage-fibroblast co-culture system
In order to compare multiple combinatorial adjuvants in a single experiment, we established a model system involving 1 × 10^5 each of TS4 (bladder cell line; ATCC, Manassas, VA), blood isolated monocytes (isolated by CD14 microbeads; Miltenyi Biotech.) and fibroblasts

| Table 1 Bladder cancer patients |
|--------------------------------|
| **Patients** | **Total** | **qPCR analysis** | **ELISA analysis** | **Chemotaxis** |
| | **N (%)** | **23(100)** | **20(100)** | **11(100)** | **3(100)** |
| Male | 15(65) | 14(70) | 6(55) | 1(33) |
| Female | 8(35) | 6(30) | 5(45) | 2(67) |
| **Tumor stage:** |  |  |  |  |
| Stage 0 | 4(17) | 4(20) | 2(18) |
| Stage 0is | 1(4) | 1(5) |
| Stage 1 | 6(26) | 5(25) | 3(27) | 1(33) |
| Stage 2 | 2(9) | 2(10) | 1(9) |
| Stage 3 | 8(35) | 6(30) | 4(36) | 2(67) |
| Stage 4 | 2(9) | 2(10) | 1(9) |
| **Prior treatment:** |  |  |  |  |
| None | 15(65) | 13(65) | 7(64) | 2(67) |
| BCG | 5(22) | 5(25) | 2(18) |
| Other treatment | 3(13) | 2(10) | 2(18) | 1(33) |
ELISA primary and secondary antibody pairs for the analysis of CCL5, CXCL8 and CXCL10, protein secretion were purchased from Peprotech, Rocky Hill, NJ. ELISA plates (Corning Inc, Corning, NY) were coated overnight at RT with 100 μL of primary antibody at 1 μg/mL, followed by washing and blocking with PBS + 4% BSA for 1 hour. 50 μL of samples were added to the wells and incubated for 1 hr and subsequently washed and incubated with 50 μL of biotinylated secondary antibodies at 0.5 μg/mL for 1 hour. The plates were washed and incubated for 30 minutes with streptavidin-HRP conjugate (Pierce Biotechnology Inc, Rockford, IL), diluted 1:10000 in wash buffer (50 mM Tris, 0.2% Tween). The plates were washed and detected with 50 μL of TMB substrate (Pierce). Reactions were stopped with 2% H₂SO₄ and 450 nm absorbance was measured, using Wallac 1420 Victor 2 microplate Reader (Perkin Elmer, Waltham, MA).

Statistical analysis
Spearman rank correlations (rho) between the mRNA of chemokine genes and cytotoxic T cell markers were calculated. Comparisons of continuous variables between groups were performed by 2 tailed, paired t test or paired Wilcoxon test using graphPad Prism 6 software. The values of P <0.05 were considered as significant.

Additional file

Additional file 1: Figure S1. Intratumoral CXCL8 expression shows strong correlation with the neutrophil marker, NCF2. Spearman (rho) analysis of the correlation between intra-tumoral mRNA expression of CXCL8 (IL-8) with Intra-tumoral expression of NCF2 (Neutrophil marker).
poly-I:C reduces CXCL10 levels in co-cultures of bladder cancer cells, macrophages and fibroblasts. TS (Bladder cell line) was co-cultured with macrophages and Fibroblasts in ratio 1:1:1 and treated with different permutations of celecoxib, IFNα plus ploy-IC reduces CXCL10 levels in co-cultures of bladder cancer cells, macrophages and fibroblasts. TS (Bladder cell line) was co-cultured with macrophages and Fibroblasts in ratio 1:1:1 and treated with different permutations of celecoxib, IFNα plus ploy-IC, and BCG. CXCL10 secretion was measured in 24 hour supernatants by ELISA. CCL2 and CXCL8 were below detection levels.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
RM was involved in concept, design and performing of experiments, and wrote the manuscript. LW was partially supported by the Tsinghua University – University of Pittsburgh Joint Education Program and China Scholarship Council. This study was supported by the NIH grants P01 CA127214 and P30 CA047904. Lilwen Wang was partially supported by the Tsinghua University – University of Pittsburgh Joint Education Program and China Scholarship Council.

Author details
1 Departments of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA.
2 Department of Urology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
3 Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
4 Department of Immunology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
5 University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.
6 Department of Surgery, University of Pittsburgh, Hillman Cancer Center, UPCI Research Pavilion, Room 1.46b, 5117 Center Avenue, Pittsburgh, PA 15213, USA.

Received: 24 November 2014 Accepted: 16 February 2015

Published online: 24 March 2015

References
1. Gohit ON, Pode D, Pizov G, Zorn KC, Katz R, Duvdevani M, et al. The natural history of bladder cancer in situ after initial response to bacillus Calmette-Guerin immunotherapy. Urol Oncol. 2009;27:258–62.
2. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol. 2008;179:53–6.
3. Morales A, Eldinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;167:891–3. discussion 893–895.
4. Zhu S, Tang Y, Li K, Shang Z, Jiang N, Nian X, et al. Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies. BMC Cancer. 2013;13:332.
5. Fuji H, Arakawa A, Utsumi D, Sumiyoshi S, Yamamoto Y, Kito K, et al. CD8+ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma. Int J Cancer. 2014;134:10239–2402.
6. Nakao M, Kitoh T, Nordfors C, Grun N, Johnson H, Hammarstedt L, et al. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One. 2012;7:e38711.
7. Friedman WH, Pines F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:296–306.
8. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge ML, Lee AH, et al. Tumor infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29:1949–55.
9. Yamada N, Ozumi S, Kikuchi E, Shingawa N, Konishi-Sakakibara J, Ishimine A, et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 2010;59:1543–9.
10. Mlecnik B, Tosolini M, Charpentong P, Kitolovsky A, Bindela G, Berger A, et al. Bioluminescent network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010;138:429–40.
11. Dudley ME, Gross CA, Langhan MW, Garcia MR, Sherry RM, Yang JC, et al. CD8+ enriched ‘young’ tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010;16:6122–31.
12. Pages F, Kirlovsky A, Mlecnik B, Assiaber M, Tosolini M, Bindela G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27:5944–51.
13. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A. 2007;104:3967–72.
14. Persma SJ, Jordanova ES, van Poelgeest MR, Kwappenberg KM, van der Hulst JM, Dilijhout JW, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007;67:354–61.
15. Galon J, Costes A, Sanchez-Cabo F, Kirlovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.
16. Sato E, Olsson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+-regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18183–43.
17. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molinder R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66.
18. Prall F, Duhkop R, Weinich V, Ostwald C, Lenz P, Nizze H, et al. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol. 2004;35:808–16.
19. Muthuswamy R, Berh E, Jenecke BF, Zeh HJ, Zureikat AH, Normolle D, et al. NF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res. 2012;72:2373–43.
20. Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H, Mori M. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol. 2005;26:41–7.
21. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakov M, Stellflug C, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009;69:3077–85.
22. Ohtani H, Jin Z, Takagawa S, Nakayama T, Yoshie O. Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. J Pathol. 2009;217:21–31.
23. Venet D, Poronzi M, Schiraldi M, Ferreli AI, Bertoni F, Doglioni C, et al. Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells. Int J Cancer. 2010;127:2300–12.
24. Martinet L, Le Gueller S, Filleron T, Lamant L, Meyer N, Rochaix P, et al. High endothelial venules (HEV)s in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. Oncoimmunology. 2012;1:829–39.
25. Lanca T, Costa MF, Goncalves-Sousa N, Rei M, Grosso AR, Penido C, et al. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic gammadelta T lymphocytes to tumor beds. J Immunol. 2013;190:6673–80.
26. Katoh H, Wang D, Daikoku T, Sun H, Uey S, Dubois RN. CCRX2-Expressing Myeloid-Derived Suppressor Cells Are Essential to Promote Colitis-Associated Tumorigenesis. Cancer Cell. 2013;24:641–44.
27. Curiel TJ, Goulios G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9.
28. Zou L, Barnett B, Safah H, Larussa VF, Fedemnon-Hogan M, Mottram P, et al. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic to tumors. Cancer Res. 2009;69:4225–32.
29. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE2-Induced CCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011;71:7463–70.
30. Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K, Kalinski P. PGE2-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells: Immunol Invest. 2012;41:655–57.
31. Reis ST, Leite KR, Piovesan LF, Pontes-Junior J, Viana NI, Abe DK, et al. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer. BMC Urol. 2012;12:18.

32. Svatek RS, Zhao XR, Morales EE, Jha MK, Tseng TY, Hugen CM, et al. Sequential Intravesical Mitomycin plus Bacillus Calmette-Guerin for Non-Muscle-Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial. Clin Caner Res. 2015;21:303–11.

33. Yamada H, Lu Y, Matsumoto T, O'Donnell MA. A novel expression of macrophage derived chemokine in human bladder cancer. J Urol. 2005;173:990–5.

34. Nepple KG, Lightfoot AJ, Rosevear HM, O'Donnell MA, Lamm DL. Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol. 2010;184:1915–9.

35. Lamm D, Brausi M, O'Donnell MA, Witjes JA. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Urol Oncol. 2014;32:35.e21–30.

36. Watchmaker PB, Berk E, Muthuswamy R, Maillard RB, Urban JA, Kirkwood JM, et al. Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells. J Immunol. 2010;184:591–7.

37. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol. 2000;164:4507–12.

38. Bisiaux A, Thiounn N, Timms MO, Eladouai A, Chang HH, Mapes J, et al. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer. J Urol. 2009;181:1571–80.

39. Mendoza-Samperio P, Alba L, Perez A. Mycobacterium bovis bacillus Calmette-Guerin (BCG)-induced CXCL8 production is mediated through PTKalpabeta-dependent activation of the IKKalpha/beta signaling pathway in epithelial cells. Cell Immunol. 2007;245:111–8.

40. Mendoza-Samperio P, Perez A, Rivera L. Mycobacterium bovis Bacillus Calmette-Guerin (BCG)-induced activation of PI3K/Akt and NF-kB signaling pathways regulates expression of CXCL10 in epithelial cells. Cell Immunol. 2009;256:12–8.

41. Heldwein KA, Liang MD, Andresen TK, Thomas KE, Marty AM, Cuesta N, et al. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J Leukoc Biol. 2003;74:277–86.

42. Barbalat R, Lau L, Locksley RM, Barton GM. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol. 2006;10:1200–7.

43. Liu YC, Simmons DP, Li X, Abbott DW, Boom WH, Harding CV. TLR2 signaling depletes IRAK1 and inhibits induction of type I IFN by TLR7/9. J Immunol. 2012;188:1019–26.

44. Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is impaired during maturation. Cancer Res. 2008;68:5972–8.